Clinical trial NCT02266524: Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders
Official title: Pharmacokinetics, Safety and Tolerability of Single Oral Doses (0.1, 0.2, 0.4 and 0.8 mg) of Tamsulosin Hydrochloride in Children With Voiding Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Urination Disorders
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-10-17
Enrollment: 48
Sex: ALL
Minimum age (years): 5
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate pharmacokinetics, safety, and tolerability of tamsulosin hydrochloride in children with voiding disorders


Eligibility criteria: Inclusion Criteria:

* Boys and girls with (or a history of) voiding disorders
* Age: 5 to 15 years
* Body weight and height ≥ 5 % and ≤95 % of normal using nomograms
* Signed and dated written informed consent by the parent or guardian and, where appropriate, informed assent by the child, prior to admission into the study in accordance with good clinical practice (GCP) and the local legislation, has been obtained

Exclusion Criteria:

* Clinically significant abnormalities found at, or before randomization at Visit 2 \[i.e., abnormal: vital signs (e.g., hypotension), ECGs, as well as significant findings during the physical examination\], as determined by the investigator
* Clinically relevant conditions including, but not limited to, the following: gastrointestinal, cardiovascular (e.g., subjects that fall above the 90th percentile according to the blood pressure nomogram in the ISF), hepatic, renal, hematologic, metabolic (including diabetes mellitus), immunological, hormonal disorders, respiratory disease or cancer
* Subjects who had surgery within the last 30 days
* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
* Subjects that have a neurological impairment or psychiatric disorder that prevents their comprehension of consent and their ability to comply with the protocol
* History of relevant orthostatic hypotension, fainting spells or blackouts. Postdural symptoms occurring (e.g., lightheadedness, dizziness, and fainting) with or without a change in blood pressure and / or pulse rate within 6 weeks of Visit 2
* Relevant acute infections, especially with regards to urinary tract infections or active genitourinary infection
* History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
* Subjects with known hypersensitivity to FLOMAX® (tamsulosin hydrochloride) or other alpha-blockers
* Use of medications classified as cytochrome P450 3A4 (CYP3A4) inhibitors and inducers within 10 days prior to administration of trial drug
* Intake of drugs with a long half-life (\> 24 hours) within less than 10 half-lives of the respective drug prior to administration
* Participation in another trial with an investigational drug within 1 month prior to administration or during the trial
* Inability to comply with dietary regimen of study center
* Pregnancy or subjects that are breast feeding
* All subjects parents and guardians in the investigator's opinion who cannot understand the terms of the informed consent form and subject information

Primary outcomes:
measure: Maximum concentration of the analyte in plasma (Cmax)
timeFrame: Up to 26 hours after drug administration
measure: Time from dosing to maximum concentration of the analyte in plasma (tmax)
timeFrame: Up to 26 hours after drug administration
measure: Area under the concentration-time curve of the analyte in plasma (AUC)
timeFrame: Up to 26 hours after drug administration
measure: Percentage of the AUC0-∞ that is obtained by extrapolation (%AUCtz-∞)
timeFrame: Up to 26 hours after drug administration
measure: Terminal rate constant of the analyte in plasma (λz)
timeFrame: Up to 26 hours after drug administration
measure: Terminal half-life of the analyte in plasma (t1/2)
timeFrame: Up to 26 hours after drug administration
measure: Mean residence time of the analyte in the body after po administration (MRTpo)
timeFrame: Up to 26 hours after drug administration
measure: Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)
timeFrame: Up to 26 hours after drug administration
measure: Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)
timeFrame: Up to 26 hours after drug administration
measure: Weight-normalized Cmax
timeFrame: Up to 26 hours after drug administration
measure: Weight-normalized AUC0-∞
timeFrame: Up to 26 hours after drug administration
measure: Weight-normalized (AUC0-tz)
timeFrame: Up to 26 hours after drug administration
Secondary outcomes:
measure: Number of patients with clinically relevant changes in physical examination
timeFrame: Pre-dose, up to 26 hours after drug administration
measure: Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate, respiratory rate)
timeFrame: Pre-dose, up to 26 hours after drug administration
measure: Number of patients with clinically relevant changes from baseline in orthostatic test
timeFrame: Pre-dose and 4 hours after drug administration
measure: Number of patients with clinically relevant changes in 12-lead ECG
timeFrame: Pre-dose, up to 26 hours after drug administration
measure: Number of patients with clinically relevant changes from baseline in laboratory tests
timeFrame: Pre-dose and 26 hours after drug administration
measure: Number of patients with adverse events
timeFrame: Up to 7 days after drug administration
measure: Global assessment of tolerability by the investigator on a 5-point rating scale
timeFrame: 26 hours after drug administration
Other outcomes:
Locations:
Study officials:
References: